Suggested remit: To appraise the clinical and cost effectiveness of 177Lu-PSMA-617 within its marketing authorisation for treating prostate-specific membrane antigen (PSMA) positive, hormone-relapsed metastatic prostate cancer previously treated with androgen receptor directed therapy (ARDT) and taxane based chemotherapy.
|
Status
|
In progress
|
| Process |
STA 2018
|
| ID number |
3840
|
Provisional Schedule
| Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
08 June 2021 - 06 July 2021 |
| In progress. DHSC referral received |
01 September 2021 |
Project Team
| Project lead |
Michelle Adhemar |
Email enquiries
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance